Form 4: Provectus Biopharmaceuticals CEO Converts Promissory Note to Preferred Stock

CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock on February 27, 2025.

Summary

• On February 27, 2025, Edward Pershing, CEO of Provectus Biopharmaceuticals, converted an 8% unsecured convertible promissory note into 67,953 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred at a price of $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the company's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.
• Following the transaction, Pershing beneficially owns 1,895,576 shares of Common Stock and $1,960,000 of Series D-1 Convertible Preferred Stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a conversion of securities. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The conversion of the promissory note into preferred stock could potentially dilute existing shareholders if the preferred stock is later converted into common stock.

Key Dates